Introduction {#section8-1176935119837547}
============

Lung cancer is the leading cause of cancer-related death.^[@bibr1-1176935119837547]^ Prognostic models that integrate multiple clinical attributes offer greater precision in predicting outcomes and can also aid in defining patient enrollment criteria for clinical trials. Several prognostic models have been developed for advanced lung cancer, but these models did not undergo external validation against multiple independent data sets.^[@bibr2-1176935119837547][@bibr3-1176935119837547][@bibr4-1176935119837547]-[@bibr5-1176935119837547]^ Given the variety of regimens considered appropriate treatment in advanced NSCLC,^[@bibr6-1176935119837547]^ this calls into question the generalizability of these models. In addition, user-friendly online implementations of diagnostic/prognostic models have greatly enhanced patient care for breast cancer,^[@bibr7-1176935119837547]^ but no such tools are available for lung cancer prognosis.

Recently, public accessibility of clinical trial data has led to a paradigm shift in clinical research. The Food and Drug Administration (FDA) Amendments Act passed in 2007 resulted in the registration and reporting of most clinical trials in the United States on [ClinicalTrials.gov](http://ClinicalTrials.gov). The Trial and Experimental Studies Transparency Act passed in 2012 required that the results of interventional trials be reported to a publicly available online database.^[@bibr8-1176935119837547]^ Shared databases are becoming a highly valuable resource for the construction, validation, and subsequent recalibration of prognostic models. One such data sharing initiative is Project Data Sphere, LLC, an independent, not-for-profit initiative of the CEO Roundtable on Cancer's Life Sciences Consortium that broadly shares de-identified comparator arm data from late-phase oncology clinical trials with researchers.^[@bibr9-1176935119837547],[@bibr10-1176935119837547]^ How to best use such valuable shared clinical trial data to improve medical research and patient care is still in the exploration stage.

The first objective of this study was to use publicly available clinical trial data to perform external validation on a previously published nomogram prognostic model, which is most commonly used for patients with advanced NSCLC.^[@bibr11-1176935119837547]^ The second objective was to develop and validate a new model for advanced NSCLC, adhering to recommendations regarding transparency in methods and performing appropriate external validation.^[@bibr4-1176935119837547]^ In addition, external validation was performed using data from multiple independent data sets to demonstrate generalizability of the model. The third objective was to develop a public online implementation of the new nomogram and a number of previously published prognostic models.^[@bibr11-1176935119837547][@bibr12-1176935119837547][@bibr13-1176935119837547]-[@bibr14-1176935119837547]^

Patients and Methods {#section9-1176935119837547}
====================

Patients {#section10-1176935119837547}
--------

De-identified NSCLC patient data from Project Data Sphere were used in model construction and validation. Application for data access was submitted to Project Data Sphere through <https://projectdatasphere.org/projectdatasphere/html/registration> and was approved. We consented to and complied with the Data User Agreement. It included 1817 patients from the comparator arms of 4 Phase III randomized clinical trials with advanced NSCLC. The 4 trials used were as follows: CA031 (n = 524), a trial comparing nab-paclitaxel and carboplatin to solvent-based paclitaxel as first-line therapy for patients with advanced NSCLC;^[@bibr15-1176935119837547]^ SUN1087 (n = 480), a trial comparing sunitinib plus erlotinib to erlotinib alone in patients with advanced NSCLC refractory to 1 or 2 chemotherapy regimens;^[@bibr16-1176935119837547]^ SAVEONCO (n = 358), a trial assessing the efficacy of semuloparin sodium for prevention of venous thromboembolism in patients with a variety of advanced solid tumors;^[@bibr17-1176935119837547]^ and VITAL (n = 455), a trial comparing (ziv-)aflibercept and docetaxel to docetaxel alone for advanced NSCLC refractory to treatment with platinum-based chemotherapy.^[@bibr18-1176935119837547]^ The characteristics of the comparator arms of the 4 trials used for this study are shown in [Table 1](#table1-1176935119837547){ref-type="table"}, with greater detail on inclusion and exclusion criteria in [Supplementary Table 1](https://journals.sagepub.com/doi/suppl/10.1177/1176935119837547). The 4 trials include patients receiving first- and/or second-line chemotherapy, with regimens varying between studies. Because this study focused on patient prognosis, only patients from the comparator arms for these trials were included. SAVEONCO includes patients with a variety of different advanced stage cancers, and only patients with lung cancer were used for the analysis. For the other 3 studies, all patients from the comparator arms were used. [Figure 1A](#fig1-1176935119837547){ref-type="fig"} shows how each of these data sets were used for both model development and validation in this study.

###### 

Summary of the comparator arm of the clinical trial data used in this study. Inclusion criteria are shown only in brief. Greater detail and information on exclusion criteria is shown in [Supplementary Table 1](https://journals.sagepub.com/doi/suppl/10.1177/1176935119837547).

![](10.1177_1176935119837547-table1)

  Study                          CA031                                                                                  SUN1087                                                                                                                              SAVEONCO                                                                                                                                      VITAL
  ------------------------------ -------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------
  Clinical trial government ID   NCT00540514                                                                            NCT00457392                                                                                                                          NCT00694382                                                                                                                                   NCT00532155
  Study dates                    Nov 2007-Aug 2013                                                                      Jul 2007-Jul 2010                                                                                                                    Jun 2008-Jan 2013                                                                                                                             Sep 2007-Jan 2011
  Stage                          III, IV                                                                                IV                                                                                                                                   I-IV                                                                                                                                          I-IV
  \#Control arm NSCLC patient    524                                                                                    480                                                                                                                                  358 of 1604 total patients                                                                                                                    455
  Patients used in analysis      466                                                                                    477                                                                                                                                  269                                                                                                                                           364
  Primary objective of study     Comparison of albumin-bound paclitaxel + carboplatin with paclitaxel + carboplatin     Comparison of erlotinib with erlotinib + SU011248 in patients previously treated with platinum-based chemotherapy                    Comparison of Semuloparin sodium with placebo for prevention of VTE in patients at high risk of VTE initiating a new course of chemotherapy   Comparison of aflibercept + docetaxel with placebo + docetaxel
  Primary outcome                Response to chemotherapy by radiologic findings (overall survival secondary outcome)   Overall survival                                                                                                                     Time to VTE-related event (overall survival secondary outcome)                                                                                Overall survival
  Inclusion criteria             Stage IIIB or IV NSCLC with no prior chemotherapy for metastatic disease               Locally advanced/metastatic NSCLC and prior treatment with no more than 2 chemotherapy regimens including a platinum-based regimen   Metastatic or locally advanced solid tumor of lung, pancreas, stomach, colon/rectum, or ovary initiating a new course of chemotherapy         Locally advanced or metastatic NSCLC with disease progression after 1 and only 1 prior chemotherapy treatment, which was platinum-based
  Line of therapy                First line                                                                             Second or third line                                                                                                                 First or second line                                                                                                                          Second line
  Cancer treatment               Paclitaxel + carboplatin                                                               Erlotinib                                                                                                                            Various chemotherapies                                                                                                                        Docetaxel
  Follow-up duration             18 months post-treatment                                                               Median 22.0 months                                                                                                                                                                                                                                                                 
  Sponsor                        Celgene                                                                                Pfizer                                                                                                                               Sanofi                                                                                                                                        Sanofi
  1-year survival rate           0.492                                                                                  0.699                                                                                                                                0.709                                                                                                                                         0.47
  Role in model development      Training                                                                               Testing                                                                                                                              Testing                                                                                                                                       Testing

Abbreviations: NSCLC, non-small-cell lung cancer; VTE, venous thromboembolism.

![Flowchart demonstrating use of various models and data sets in this study. (A) CA031 was used as a training set for the new nomogram. SUN1087, SAVEONCO, and VITAL were used as external validation sets for the new nomogram. All models involved in this study are implemented on a web portal. (B) Exploratory survival analysis for the 4 data sets used in this study.](10.1177_1176935119837547-fig1){#fig1-1176935119837547}

Nomogram development {#section11-1176935119837547}
--------------------

The new nomogram was developed using CA031^15^ as a training set and then validated in 3 independent validation sets: SUN1087,^[@bibr16-1176935119837547]^ SAVEONCO,^[@bibr17-1176935119837547]^ and VITAL.^[@bibr18-1176935119837547]^ Clinical variables that were present in both CA031^15^ and at least 1 validation data set were selected as potential co-variables in the model. Overall survival was used as the primary outcome for the nomogram model. Univariate analyses were first used to establish the associations between potential predictors and overall survival in the training set. Co-variables with statistically significant associations with survival (*P*-value \< 0.05) in the univariate analysis were then used as co-variables in a multivariate Cox model, using overall survival as the outcome variable. LASSO (Least Absolute Shrinkage and Selection Operator) penalty^[@bibr19-1176935119837547],[@bibr20-1176935119837547]^ was used in the multivariate Cox model to further remove possible redundancy (by reducing the number of variables) and improve the robustness of the model. The tuning parameter (cost parameter) for the LASSO penalty was determined by cross-validation within the training set. The fitted multivariate Cox model was used as the final nomogram model. All computations were conducted in the R environment. The fitted nomogram used the covariates as input and generated a risk score for each new patient in the testing sets.

Survival analysis {#section12-1176935119837547}
-----------------

Overall survival time was calculated from the date of randomization until death or the date of last follow-up. Survival curves were estimated using the Kaplan-Meier product-limit method.^[@bibr21-1176935119837547]^ Differences in the survival curves were compared using a log-rank test. A univariate Cox proportional-hazards model^[@bibr22-1176935119837547]^ was used to determine the association between a continuous variable and overall survival in univariate analysis.

Validation criterion {#section13-1176935119837547}
--------------------

For each study, patients without histology demonstrating adenocarcinoma (AD), squamous cell carcinoma (SCC), and large cell carcinoma (LC) of the lung, such as those with uncertain histology, were excluded. For the purposes of validation, missing data were imputed as the population median. Four criteria were used for the evaluation of the prediction performance of Hoang et al's^[@bibr11-1176935119837547]^ model and our new nomogram:

1.  *Survival difference between predicted high- and low-risk groups*: first, risk score was calculated using the nomogram for each patient from the testing sets based on the patients' covariate values. The patients in each testing set were assigned into a high- or low-risk group based on their risk score calculated by the nomogram, with the median risk score from the training set as the cut-off value. The log-rank *P*-value was used to determine whether survival differences existed between the high- and low-risk groups in each testing set.

2.  *Concordance index*: concordance is defined as the probability of agreement for any 2 randomly chosen patients, where agreement means that the patient with the shorter survival time of the 2 also has the larger risk score. For survival data, some of the pairs are incomparable. For comparable pairs, patients may also be tied. The final concordance is $(agree + tied/2)/(agree + disagree + tied).$

3.  *Integrated area under the curve (AUC) of time-dependent receiver operating characteristics (ROC)*^[@bibr23-1176935119837547],[@bibr24-1176935119837547]^: the area under the ROC curve at each month from the 6th to the 18th month, the span in which most patients' follow-up times fell, was calculated, and these AUCs were integrated into a single score (integrated AUC). The time-dependent ROC curve was calculated by Inverse Probability Censoring Weighted (IPCW) estimation. Weights were computed by the Kaplan-Meier estimator of the censoring distribution. The time-dependent AUCs of different time points were integrated into a single score (AUC).

4.  *Calibration plot*: for classification models, a calibration plot is often used to help visualize how consistent the predicted probabilities (ie, the predicted survival probabilities in this case) are with observed event rates (the event in this case is defined as being alive). To construct the calibration plots, we implemented the *calibration* function from R package *caret*. The following steps were used for each nomogram:The patients in the testing data set were split into 20 roughly equal groups by their predicted survival probabilities.The number of samples with true results (alive or dead at specified time points) equal to the event class (alive) were determined.The event rate was determined for each bin.

The generated calibration plot is essentially a scatter plot of the observed event rate by the mid-point predicted probability value of the bins. The confidence intervals on the estimated proportions are constructed using the binomial test.

Implementation of previously published models {#section14-1176935119837547}
---------------------------------------------

To facilitate clinician, researcher, and patient utilization of the prognostic models published previously and of our new model, we created a user-friendly Web server for our model together with the 4 published prognostic models for lung cancer^[@bibr11-1176935119837547][@bibr12-1176935119837547][@bibr13-1176935119837547]-[@bibr14-1176935119837547]^ shown in [Supplementary Table 2](https://journals.sagepub.com/doi/suppl/10.1177/1176935119837547) (<http://lce.biohpc.swmed.edu/lungcancer/nomogram>). Details of the implementations of the 4 published models are described in [Supplementary Table 2](https://journals.sagepub.com/doi/suppl/10.1177/1176935119837547).

Results {#section15-1176935119837547}
=======

Clinical trial and patient population characteristics {#section16-1176935119837547}
-----------------------------------------------------

Thirty-one patients from CA031^15^ were excluded for having a cancer type other than AD, SCC, and LC. Three patients were excluded from this study because of a lack of follow-up information or because \>50% of covariates were missing. One patient was excluded from the VITAL cohort because survival information was missing. Kaplan-Meier plots for follow-up time and follow-up status for all 4 studies are shown in [Figure 1B](#fig1-1176935119837547){ref-type="fig"}. The 1-year survival rates for these 4 studies range from 0.47 to 0.709. A summary of the data distribution for the 21 variables selected for evaluation is shown in [Supplementary Table 3](https://journals.sagepub.com/doi/suppl/10.1177/1176935119837547).

Validation of a previously published nomogram {#section17-1176935119837547}
---------------------------------------------

As a first step, we performed validation of the previously published nomogram by Hoang et al^[@bibr11-1176935119837547]^ in 2005 with data from CA031,^[@bibr15-1176935119837547]^ which contains all variables used in the nomogram. Hoang et al's prognosis is the most cited and used prognostic model for advanced NSCLC, but no independent validations have been performed since its publication in 2005 due to a lack of validation cohorts. [Supplementary Figure 1](https://journals.sagepub.com/doi/suppl/10.1177/1176935119837547) shows that patients in the CA031 cohort in the high-risk group predicted by the Hoang model have significantly worse survival outcomes compared with those in the low-risk group (*P* = 4.58e−9, log-rank test), with the high- and low-risk groups' 1-year survival rates being 0.332 and 0.549, respectively. The integrated area under the ROC curve was 0.646 and the concordance index was 0.611 ([Supplementary Figure 2(a)](https://journals.sagepub.com/doi/suppl/10.1177/1176935119837547)). This shows that the Hoang prognostic model was valid in an independent NSCLC cohort.

Developing a new prognostic nomogram {#section18-1176935119837547}
------------------------------------

Results of univariate analysis of the association between each eligible variable and patient overall survival within CA031^15^ are displayed in [Table 2](#table2-1176935119837547){ref-type="table"}. In total, 12 variables had a *P*-value \< 0.05 and were included in the LASSO Cox regression model, and 9 variables remained after variable selection using LASSO penalty. These variables were as follows: sex, Eastern Cooperative Oncology Group (ECOG) score, peritoneal metastasis, skin metastasis, liver metastasis, hemoglobin level, white blood cell count, lymphocyte percentage, and large cell histology. The nomogram was constructed by fitting a multivariate Cox proportional hazard model using these variables from CA031.^[@bibr15-1176935119837547]^ [Table 3](#table3-1176935119837547){ref-type="table"} shows the hazard ratio (95% confidence interval) and *P*-value of each variable within this multivariate model, of which 5 *P*-values remained \<0.05.

###### 

Univariate analysis of prognostic survival for the CA031 study. The columns are variable name, univariate likelihood ratio test *P*-value, and hazard ratio from a univariate test. Variables marked with an asterisk are logarithm transformed.

![](10.1177_1176935119837547-table2)

  Variable                             Univariate *P*-value   Hazard ratio (95% confidence interval)
  ------------------------------------ ---------------------- ----------------------------------------
  Stage                                                       
   IV vs III                           1.53e−01               1.21 (0.93-1.58)
  Sex                                                         
   Men vs Women                        5.99e−06               1.79 (1.37-2.34)
  Histological type                                           
   LC vs AD                            5.75e−01               1.22 (0.63-2.36)
   SCC vs AD                           3.20e−04               1.49 (1.20-1.85)
  Body mass index (kg/m^2^)            2.35e−01               0.99 (0.96-1.01)
  Age (years)                          4.96e−01               1.00 (0.99-1.02)
  ECOG score                           1.33e−05               1.84 (1.37-2.48)
  Brain metastasis                     4.87e−01               0.80 (0.41-1.55)
  Peritoneal metastasis                1.15e−06               1.88 (1.48-2.39)
  Skin metastasis                      2.05e−02               2.14 (1.20-3.82)
  Bone metastasis                      1.95e−01               1.19 (0.92-1.55)
  Liver metastasis                     8.35e−06               1.81 (1.41-2.32)
  Glucose (mg/dL)\*                    3.28e−01               1.35 (0.74-2.46)
  Alkaline phosphatase (U/L)\*         6.84e−01               0.96 (0.80-1.16)
  Alanine aminotransferase (U/L)\*     5.04e−01               1.07 (0.87-1.32)
  Aspartate aminotransferase (U/L)\*   9.09e−02               1.31 (0.96-1.78)
  Creatinine (mg/dL)                   8.06e−02               1.65 (0.94-2.89)
  Total bilirubin (mg/dL)\*            2.16e−02               0.74 (0.58-0.96)
  Hemoglobin (g/dL)                    1.05e−03               0.89 (0.83-0.96)
  White blood cell count (K/uL)\*      9.10e−15               3.49 (2.54-4.79)
  Neutrophil percentage (0%-100%)      3.22e−07               19.9 (6.16-64.3)
  Lymphocyte percentage (0%-100%)      5.48e−08               0.03 (0.01-0.10)

Abbreviations: LC, large cell carcinoma; SCC, squamous cell carcinoma; AD, adenocarcinoma.

###### 

Hazard ratios (HR) and 95% confidence intervals of nomogram parameters. Variables marked by an asterisk are logarithm transformed.
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  Variable                          HR (95% confidence interval)   *P*-value
  --------------------------------- ------------------------------ -----------
  Sex                                                              
   Men vs Women                     1.71 (1.30-2.26)               1.39e−4
  Histological type                                                
   LC vs AD and SCC                 1.46 (0.75-2.85)               2.70e−1
  ECOG score                        1.35 (0.99-1.82)               5.55e−2
  Peritoneal metastasis             1.76 (1.36-2.28)               1.54e−5
  Skin metastasis                   1.78 (0.98-3.23)               5.97e−2
  Liver metastasis                  1.53 (1.19-1.98)               1.05e−3
  Hemoglobin (g/dL)                 0.90 (0.83-0.96)               3.32e−3
  White blood cell count (K/uL)\*   2.48 (1.74-3.53)               4.52e−7
  Lymphocyte percentage (0%-100%)   0.28 (0.06-1.25)               9.48e−2

Abbreviations: LC, large cell carcinoma; SCC, squamous cell carcinoma; AD, adenocarcinoma; ECOG, Eastern Cooperative Oncology Group.

Validation of the new prognostic nomogram {#section19-1176935119837547}
-----------------------------------------

The proposed nomogram was developed using the CA031^15^ patient cohort as a training set and validated in 3 independent patient cohorts. The validation results are presented in [Figure 2](#fig2-1176935119837547){ref-type="fig"} and [Supplementary Figure 2(b) to (d)](https://journals.sagepub.com/doi/suppl/10.1177/1176935119837547). In [Figure 2](#fig2-1176935119837547){ref-type="fig"}, the risk groups are defined using the median value of the predicted 2-year survival probabilities. The Hoang et al nomogram was also validated on these 3 cohorts for comparison. In the SUN1087^16^ patient cohort, the continuous risk score output by the new nomogram achieved an integrated area under the ROC curve of 0.83 from the 6th month to the 18th month and a concordance index of 0.717 ([Supplementary Figure 2(b)](https://journals.sagepub.com/doi/suppl/10.1177/1176935119837547)). The log-rank *P*-value was 3.87e−11, with the high- and low-risk groups' 1-year survival rates being 0.456 and 0.773, respectively. In the SAVEONCO^[@bibr17-1176935119837547]^ patient cohort, the integrated area under the ROC curve was 0.755 and the concordance index was 0.678 ([Supplementary Figure 2(c)](https://journals.sagepub.com/doi/suppl/10.1177/1176935119837547)). The log-rank *P*-value was 4.94e−6, with the high- and low-risk groups' 1-year survival rates being 0.568 and 0.785, respectively. In the VITAL^[@bibr18-1176935119837547]^ patient cohort, the integrated area under the ROC curve was 0.723, the concordance index was 0.654 ([Supplementary Figure 2(d)](https://journals.sagepub.com/doi/suppl/10.1177/1176935119837547)), and the log-rank *P*-value was 1.36e−11, with the high- and low-risk groups' 1-year survival rates being 0.278 and 0.574, respectively. The integrated AUC, concordance index, and log-rank *P*-value measurements from the 3 independent testing cohorts showed that the proposed nomogram works well in the 3 test data sets, indicating the robustness of the prediction model. [Supplementary Table 4](https://journals.sagepub.com/doi/suppl/10.1177/1176935119837547) provides a summary of these results.

![Evaluation of nomograms by log-rank test. Evaluation of previous nomogram and new nomogram on testing data sets including (A, B) the SUN1087 study, (C, D) the SAVEONCO study, and (E, F) the VITAL study. Each panel shows the separation of the Kaplan-Meier estimator by the dichotomized risk score for the testing patients, and *P*-values were calculated based on log-rank test for the statistical significance of survival time difference between the predicted high- and low-risk groups. The risk groups are classified based on the median of predicted survival rates.](10.1177_1176935119837547-fig2){#fig2-1176935119837547}

We also validated the performance of our new nomogram as well as the Hoang et al nomogram using the calibration plot ([Figure 3](#fig3-1176935119837547){ref-type="fig"}). From both [Figures 2](#fig2-1176935119837547){ref-type="fig"} and [3](#fig3-1176935119837547){ref-type="fig"}, we can clearly see that our new nomogram outperforms the Hoang model at least on these 3 neutral data sets.

![Calibration plots. Calibration plots of previous nomogram and new nomogram were generated using 3 testing data sets: (A, B) the SUN1087 study, (C, D) the SAVEONCO study, and (E, F) the VITAL study.](10.1177_1176935119837547-fig3){#fig3-1176935119837547}

Building a user-friendly Web server for the updated and previous nomograms {#section20-1176935119837547}
--------------------------------------------------------------------------

We have also provided an online version of this nomogram ([Supplementary Figure 3](https://journals.sagepub.com/doi/suppl/10.1177/1176935119837547)) to facilitate its widespread use by physicians and researchers (<http://lce.biohpc.swmed.edu/lungcancer/nomogram/index.php>). Online implementations of several previously developed models are also available^[@bibr11-1176935119837547][@bibr12-1176935119837547][@bibr13-1176935119837547]-[@bibr14-1176935119837547]^ ([Supplementary Figure 4](https://journals.sagepub.com/doi/suppl/10.1177/1176935119837547)). Comparison of overall survival probabilities can be made between these nomograms by inputting patients' clinical features and reading output generated by the Web server.

Discussion {#section21-1176935119837547}
==========

The landscape of lung cancer patients and treatment has shifted over time. Therefore, it is of value to provide more updated nomograms given new data. We developed and validated a prognostic model for patients with advanced stage NSCLC treated with chemotherapy using up-to-date patient data collected after 2007. The nomogram was built using data from CA031^15^ and validated with 3 independent clinical trials. The new nomogram meets the guidelines for AJCC endorsement.^[@bibr25-1176935119837547]^ A wide range of clinical features have been incorporated for use in prognostic models in the past, and a detailed comparison with other published prognostic models is presented in [Supplementary Table 2](https://journals.sagepub.com/doi/suppl/10.1177/1176935119837547). Robust external validation demonstrated discriminatory power in the nomogram through 3 different statistical measures for each validation data set. First, dichotomization of patients into high- and low-risk subgroups based on their calculated nomogram score showed a statistically significant difference in the survival curves between groups. Second, the nomogram had a high c-index in each validation set, which means that for any given pair of patients, there is a high probability that the nomogram score correctly predicts which patient will have better survival. Third, the nomogram performed well by area under the ROC curve at every measured time-point, indicating that the nomogram had a strong ability to predict whether or not a patient would be alive at a given time after randomization. In addition, our analyses demonstrated the good calibration performance of our new nomogram.

Each of the validation data sets contained patients receiving different types of treatment, including first-, second-, and third-line treatments and both cytotoxic and targeted regimens. Survival analysis thus unsurprisingly demonstrated considerable heterogeneity in survival characteristics between the studies used to validate the nomogram. In spite of this, the proposed nomogram demonstrated accuracy and robust performance across multiple testing data sets. A major strength of this study, therefore, is that we have demonstrated the external validity of our model in a broad range of clinical scenarios. The 3 testing data sets include patients on both targeted and non-targeted therapies. This is in contrast to many previously published prognostic tools for advanced stage NSCLC, which did not undergo external validation and therefore have not been proven to be generalizable to the disparate situations that clinicians are likely to encounter.^[@bibr2-1176935119837547]^

Moreover, in the modern treatment era, conventional cytotoxic chemotherapy still remains a component of treatment for almost all patients with lung cancer, although immunotherapy and molecular-targeted therapy are more and more commonplace. Only a small minority of patients (about 20%) will have a druggable kinase alteration such as epidermal growth factor receptor (EGFR) or anaplastic large-cell lymphoma kinase (ALK). For example, the FDA recently limited the indication of EGFR inhibitor Erlotinib to only those cases with specific EGFR mutations. And, although immunotherapy has become a treatment option for patients, only about 25% of patients have high-level (⩾ 50%) PDL1 expression for which first-line immunotherapy is better than chemotherapy. Therefore, the variables included in our proposed model should be applicable to the general patient population. However, in the future, it will be interesting to consider the key biomarkers in NSCLC, including EGFR genotype, ALK genotype, and PDL1 status, together with clinical covariates for patient prognosis when such data sets with large sample sizes are available.

One challenge for using public data arose from the missing data across cohorts. Performance status (ECOG or Karnofsky) is the only variable included in all 5 prognostic models, stressing the importance of this variable for prognosis. But, there is a certain degree of dissimilarity between the other variables included between the 5 models, which calls for a direct comparison of these models. However, this is not possible within the scope of this study as some clinical variables that are frequently used in prognostic modeling of NSCLC, such as serum lactate dehydrogenase, were not available from the public clinical trial data.

By implementing prognostic models on a Web server, we provide an easy way for researchers and clinicians to access the predicted overall survival probabilities and also to make straightforward comparisons between survival probabilities generated by different models. Our hope is that greater transparency in data reporting for clinical trials will be accompanied by greater access for clinicians to prognostic models that can enhance precise tailoring of patient management.

Supplemental Material {#section22-1176935119837547}
=====================

###### Suppl_material -- Supplemental material for Development and Validation of a Nomogram Prognostic Model for Patients With Advanced Non-Small-Cell Lung Cancer

###### 

Click here for additional data file.
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